GlassScriptPhysician profile
David M Erickson
NPI 1508363664
$3,307.90
in general payments reported to CMS, 2019-2025
36 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $319 · 2023: $1,014 · 2024: $914 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.83 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $565.76 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $444.07 | 2023-2025 | |
| Astellas Pharma US INC | $210.43 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $209.39 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $190.58 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $149.63 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $143.37 | 2023-2025 | Rexulti |
| Silk Road Medical, INC. | $142.86 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novo Nordisk INC | $136.80 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $100.98 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $98.23 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.38 | 2023-2025 | Jardiance |
| Insulet Corporation | $86.48 | 2024-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $86.10 | 2023 | |
| Dexcom, INC. | $67.23 | 2022-2025 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.